XTX101 Monotherapy and XTX101 & Atezolizumab Combination Therapy in Advanced Solid Tumors - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called XTX101 (the study drug) is a safe and effective option for people who have advanced tumors or metastatic microsatellite stable colorectal cancer. We want to see how well it works on its own and in combination with a drug called atezolizumab.
What is the Condition Being Studied?
Advanced Solid Tumors or Metastatic Microsatellite Stable Colorectal Cancer
Who Can Participate in the Study?
Adults ages 18+ who have one of the following forms of cancer:
- Advanced solid tumors; OR
- Metastic microsatellite stable colorectal cancer
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Get a random assignment (like a coin flip) to either take the study drug on its own or in combination with atezolizumab
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
Study Details
Full Title
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00115574
NCT:
NCT04896697
Phase
Phase
I/II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment